Baird analyst Brian Skorney calls Sarepta Therapeutics (NASDAQ: SRPT) DMD gene therapy results "really positive."Skorneycommented, "The initial results, in two ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE